What AI says about Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company that develops RNA interference therapeutics to treat diseases at their source.
AI mentioned Alnylam Pharmaceuticals from October 2025 to June 2026.
Questions and answers
- AI picks most
- What are the latest affordable advancements in biopharma for treating rare diseases?AI picks U.S. Food and Drug Administration (FDA) and 6 more about as often
Excerpts where Alnylam Pharmaceuticals appeared in the AI's answer
Google AI ModeJun 10, 2026, Google AI Mode Alnylam Pharmaceuticals: Targeting genetically driven neurodegenerative and rare systemic diseases with highly efficient RNA therapeutics.
Google AI ModeJun 2, 2026, Google AI Mode Driven by major shifts at companies like Alnylam Pharmaceuticals , RNA interference (RNAi) and ASO therapies use a plug-and-play approach.
Alnylam Pharmaceuticals in AI answers
What are the latest affordable advancements in biopharma for treating rare diseases?
ChatGPTChatGPTNo answer mentioning Alnylam Pharmaceuticals
Google AI ModeGoogle AI Mode· Jun 10, 2026
Alnylam Pharmaceuticals: Targeting genetically driven neurodegenerative and rare systemic diseases with highly efficient RNA therapeutics.
Sites AI cites
None of these answers cited alnylam.com. AI cited pmc.ncbi.nlm.nih.gov, youtube.com, and finance.yahoo.com.
Brands AI mentions
AI mentioned Alnylam Pharmaceuticals most often alongside Amvuttra, Insilico Medicine, and Recursion.
